IL129938A - A method for formulating a consequence of tetrahydropyridine, a mixture of crystalline forms obtained by this method and pharmaceutical preparations containing this mixture - Google Patents

A method for formulating a consequence of tetrahydropyridine, a mixture of crystalline forms obtained by this method and pharmaceutical preparations containing this mixture

Info

Publication number
IL129938A
IL129938A IL12993897A IL12993897A IL129938A IL 129938 A IL129938 A IL 129938A IL 12993897 A IL12993897 A IL 12993897A IL 12993897 A IL12993897 A IL 12993897A IL 129938 A IL129938 A IL 129938A
Authority
IL
Israel
Prior art keywords
mixture
ethyl
naphthyl
trifluoromethyl
tetrahydropyridine hydrochloride
Prior art date
Application number
IL12993897A
Other languages
English (en)
Hebrew (he)
Other versions
IL129938A0 (en
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL129938A0 publication Critical patent/IL129938A0/xx
Publication of IL129938A publication Critical patent/IL129938A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12993897A 1996-12-23 1997-12-23 A method for formulating a consequence of tetrahydropyridine, a mixture of crystalline forms obtained by this method and pharmaceutical preparations containing this mixture IL129938A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
PCT/FR1997/002393 WO1998028271A1 (fr) 1996-12-23 1997-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (2)

Publication Number Publication Date
IL129938A0 IL129938A0 (en) 2000-02-29
IL129938A true IL129938A (en) 2004-06-20

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12993897A IL129938A (en) 1996-12-23 1997-12-23 A method for formulating a consequence of tetrahydropyridine, a mixture of crystalline forms obtained by this method and pharmaceutical preparations containing this mixture

Country Status (39)

Country Link
EP (1) EP0950050B1 (zh)
JP (2) JP4499188B2 (zh)
KR (1) KR100586670B1 (zh)
CN (1) CN1129580C (zh)
AR (1) AR009672A1 (zh)
AT (1) ATE307802T1 (zh)
AU (1) AU736697B2 (zh)
BR (1) BR9714081A (zh)
CA (1) CA2275596C (zh)
CO (1) CO5070688A1 (zh)
CZ (1) CZ296689B6 (zh)
DE (1) DE69734460T2 (zh)
DK (1) DK0950050T3 (zh)
DZ (1) DZ2383A1 (zh)
EE (1) EE04188B1 (zh)
EG (1) EG21567A (zh)
ES (1) ES2251038T3 (zh)
FR (1) FR2757543B1 (zh)
HK (1) HK1024002A1 (zh)
HR (1) HRP970699B1 (zh)
HU (1) HU227425B1 (zh)
IL (1) IL129938A (zh)
IN (1) IN186976B (zh)
IS (1) IS2357B (zh)
MY (1) MY118015A (zh)
NO (1) NO312364B1 (zh)
NZ (1) NZ336130A (zh)
PL (1) PL190494B1 (zh)
RS (1) RS49882B (zh)
RU (1) RU2192416C2 (zh)
SA (1) SA98180971B1 (zh)
SI (1) SI0950050T1 (zh)
SK (1) SK285088B6 (zh)
TR (1) TR199901363T2 (zh)
TW (1) TW518322B (zh)
UA (1) UA60324C2 (zh)
UY (1) UY24825A1 (zh)
WO (1) WO1998028271A1 (zh)
ZA (1) ZA9711576B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
EP2546286B1 (en) 2010-03-12 2019-09-25 Nippon Shokubai Co., Ltd. Method for manufacturing a water-absorbing resin
ES2604405T3 (es) * 2011-04-15 2017-03-06 Emcure Pharmaceuticals Limited Un procedimiento para rilpivirina mejorado

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
NO993076L (no) 1999-06-22
YU28999A (sh) 2003-01-31
DK0950050T3 (da) 2006-01-23
EG21567A (en) 2001-12-31
SI0950050T1 (sl) 2006-04-30
UA60324C2 (uk) 2003-10-15
EE9900264A (et) 2000-02-15
JP2009197022A (ja) 2009-09-03
EP0950050B1 (fr) 2005-10-26
FR2757543A1 (fr) 1998-06-26
TR199901363T2 (xx) 1999-08-23
IS2357B (is) 2008-04-15
BR9714081A (pt) 2000-05-09
NZ336130A (en) 2001-01-26
HK1024002A1 (en) 2000-09-29
NO312364B1 (no) 2002-04-29
CZ229299A3 (cs) 1999-09-15
SA98180971B1 (ar) 2006-09-13
AU736697B2 (en) 2001-08-02
DZ2383A1 (fr) 2002-12-28
CO5070688A1 (es) 2001-08-28
KR100586670B1 (ko) 2006-06-07
MY118015A (en) 2004-08-30
SK285088B6 (sk) 2006-06-01
CN1241180A (zh) 2000-01-12
ZA9711576B (en) 1998-06-25
AU5668498A (en) 1998-07-17
ES2251038T3 (es) 2006-04-16
PL334256A1 (en) 2000-02-14
HU227425B1 (en) 2011-05-30
JP4499188B2 (ja) 2010-07-07
HUP0001387A2 (hu) 2000-09-28
SK82899A3 (en) 1999-12-10
HRP970699A2 (en) 1998-10-31
EP0950050A1 (fr) 1999-10-20
NO993076D0 (no) 1999-06-22
RS49882B (sr) 2008-08-07
HUP0001387A3 (en) 2002-03-28
DE69734460D1 (de) 2005-12-01
WO1998028271A1 (fr) 1998-07-02
IL129938A0 (en) 2000-02-29
RU2192416C2 (ru) 2002-11-10
UY24825A1 (es) 1998-04-21
CN1129580C (zh) 2003-12-03
IS5076A (is) 1999-06-10
HRP970699B1 (en) 2007-03-31
CA2275596A1 (en) 1998-07-02
CZ296689B6 (cs) 2006-05-17
EE04188B1 (et) 2003-12-15
CA2275596C (en) 2005-10-11
AR009672A1 (es) 2000-04-26
DE69734460T2 (de) 2006-07-06
IN186976B (zh) 2001-12-22
PL190494B1 (pl) 2005-12-30
ATE307802T1 (de) 2005-11-15
FR2757543B1 (fr) 1999-04-02
KR20000069504A (ko) 2000-11-25
JP2001507012A (ja) 2001-05-29
TW518322B (en) 2003-01-21

Similar Documents

Publication Publication Date Title
JP2009102345A (ja) 結晶性ジベンゾチアゼピン誘導体およびその抗精神病薬としての使用
WO2011050962A1 (en) Acid addition salts of lenalidomide
CA2275596C (en) Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms
US6489334B2 (en) Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
EP1858847A1 (en) Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
JP2009280581A (ja) テトラヒドロピリジン誘導体の微粒子形態
JPH05229945A (ja) 特定の結晶変態を有する１，４−ジヒドロ−２，６−ジメチル−４−（３−ニトロフエニル）−３，５−ピリジンジカルボン酸イソプロピル−（２−メトキシエチル）を含有する薬学的調製物
AU612344B2 (en) - 8-heterocyclo-ergoline derivatives useful in the treatment of extrapyramidal syndromes
MXPA99005620A (en) Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms
MXPA99005621A (en) Micro-particulate form of a tetrahydropyridin derivative
WO2003042161A1 (en) Venlafaxine hydrochloride polymorphs
HRP970701A2 (en) Micro-particulate form of a tetrahydropyridin derivative
MXPA00010435A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA99005108A (en) 1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating alzheimer's disease
MXPA00009884A (en) Paroxetine maleate
MXPA00000511A (en) A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees